

1. Saigusa D, Honda T, Iwasaki Y, et al. Lipidomic and metabolic profiling of plasma and plasma-derived extracellular vesicles by UHPLC-MS/MS. *Med Mass Spectrom.* 2022;6(2):126–137. doi:10.24508/mms.2022.11.007
2. Kawame H, Fukushima A, Fuse N, et al. The return of individual genomic results to research participants: design and pilot study of Tohoku Medical Megabank Project. *J Hum Genet.* 2022;67(1):9–17. doi:10.1038/s10038-021-00952-8
3. Mori T, Ueno K, Tokunaga K, et al. A single-nucleotide-polymorphism in the 5′ -flanking region of MSX1 gene as a predictive marker candidate for platinum-based therapy of esophageal carcinoma. *Ther Adv Med Oncol.* 2022;14:175883592210805. doi:10.1177/17588359221080580
4. Ogishima S. [Development of Biobank Network in Japan]. *Gan To Kagaku Ryoho.* 2022;49(2):125–128. <http://www.ncbi.nlm.nih.gov/pubmed/35249043>
5. Egawa-Takata T, Ueda Y, Ito K, et al. Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma. *Cancer Sci.* 2022;113(5):1693–1701. doi:10.1111/cas.15310
6. Turlousse DM, Narita K, Miura T, et al. Characterization and Demonstration of Mock Communities as Control Reagents for Accurate Human Microbiome Community Measurements. Jensen PA, ed. *Microbiol Spectr.* 2022;10(2). doi:10.1128/spectrum.01915-21
7. Matsuo K, Klar M, Barakzai SK, et al. Utilization of sentinel lymph node biopsy in the early ovarian cancer surgery. *Arch Gynecol Obstet.* 2022;307(2):525–532. doi:10.1007/s00404-022-06595-0
8. Grapotte M, Saraswat M, Bessière C, et al. Author Correction: Discovery of widespread transcription initiation at microsatellites predictable by sequence-based deep neural network. *Nat Commun.* 2022;13(1):1200. doi:10.1038/s41467-022-28758-y
9. Shimada M, Tsuji K, Shigeta S, et al. Rethinking the significance of surgery for uterine cervical cancer. *J Obstet Gynaecol Res.* 2022;48(3):576–586. doi:10.1111/jog.15112
10. Endo S, Shigeta S, Tokunaga H, et al. A Retrospective Analysis of Clinical Biomarkers for Olaparib Maintenance Therapy in Patients with Recurrent Ovarian Cancer. *Tohoku J Exp Med.* 2022;258(1):2022.J050. doi:10.1620/tjem.2022.J050
11. Matsuo K, Klar M, Ciccone MA, et al. Incorporation of sentinel lymph node biopsy in cervical cancer surgery: Recent U.S. trends. *Eur J Surg Oncol.* 2022;48(6):1407–1413. doi:10.1016/j.ejso.2022.02.018

12. Shigeta S, Shimada M, Tsuji K, et al. Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group. *Int J Clin Oncol*. 2022;27(9):1507–1515. doi:10.1007/s10147-022-02198-6
13. Matsuyama T, Narita A, Takanashi M, et al. Visualization of estimated prevalence of CES-D positivity accounting for background factors and AIS scores. *Sci Rep*. 2022;12(1):17656. doi:10.1038/s41598-022-22266-1
14. Li X, Ono C, Warita N, et al. Heart Rate Information-Based Machine Learning Prediction of Emotions Among Pregnant Women. *Front Psychiatry*. 2022;12. doi:10.3389/fpsyt.2021.799029
15. Shigeta S, Watanabe Y, Suzuki F, et al. MicroRNA-152 Regulates Endometrial Serous Carcinoma Cell Motility by Suppressing Matrix Metalloproteinase 10 Expression. *Tohoku J Exp Med*. 2022;256(3):256.249. doi:10.1620/tjem.256.249
16. Ragab OM, Mehta S, Nusbaum DJ, et al. Incorporation of vaginal brachytherapy to external beam radiotherapy in adjuvant therapy for high-risk early-stage cervical cancer: A comparative study. *Brachytherapy*. 2022;21(2):141–150. doi:10.1016/j.brachy.2021.09.006
17. Nagai T, Shimada M, Tokunaga H, Ishikawa M, Yaegashi N. Clinical issues of surgery for uterine endometrial cancer in Japan. *Jpn J Clin Oncol*. 2022;52(4):346–352. doi:10.1093/jjco/hyab211
18. Shibuya Y, Shimada M, Tsuji K, et al. Prognostic factors of 2018 FIGO stage IB–IIA cervical cancer with absence of high/ intermediate surgical-pathological risk factors. *Jpn J Clin Oncol*. Published online August 1, 2022. doi:10.1093/jjco/hyac125
19. Shigeta S, Shimada M, Tsuji K, et al. Correction to: Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group. *Int J Clin Oncol*. 2022;27(9):1516–1516. doi:10.1007/s10147-022-02211-y
20. Kukimoto I, Onuki M, Yamamoto K, et al. Regional differences in human papillomavirus type 52 prevalence among Japanese women with cervical intraepithelial neoplasia. *Jpn J Clin Oncol*. Published online August 6, 2022. doi:10.1093/jjco/hyac127
21. Kuga A, Tsuchida K, Panda H, et al. The β -TrCP-Mediated Pathway Cooperates with the Keap1-Mediated Pathway in Nrf2 Degradation In Vivo. *Mol Cell Biol*. 2022;42(7). doi:10.1128/mcb.00563-21
22. Shoji T, Takatori E, Nagasawa T, et al. Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study). *Int J Clin Oncol*. 2022;27(12):1874–1880. doi:10.1007/s10147-022-02246-1

23. Patel SD, Anand D, Motohashi H, Katsuoka F, Yamamoto M, Lachke SA. Deficiency of the bZIP transcription factors Mafg and Mafk causes misexpression of genes in distinct pathways and results in lens embryonic developmental defects. *Front Cell Dev Biol.* 2022;10. doi:10.3389/fcell.2022.981893
24. Asano H, Oda K, Yoshihara K, et al. Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052). *J Gynecol Oncol.* 2022;33(4). doi:10.3802/jgo.2022.33.e55
25. Okazaki K, Anzawa H, Katsuoka F, Kinoshita K, Sekine H, Motohashi H. CEBPB is required for NRF2-mediated drug resistance in NRF2-activated non-small cell lung cancer cells. *J Biochem.* 2022;171(5):567–578. doi:10.1093/jb/mvac013
26. Fuse N, Sakurai M, Motoike IN, et al. Genome-wide Association Study of Axial Length in Population-based Cohorts in Japan. *Ophthalmol Sci.* 2022;2(1):100113. doi:10.1016/j.xops.2022.100113
27. Terauchi Y, Nagayama M, Tanaka T, et al. Adsorption Kinetics and Self-Assembled Structures of *Aspergillus oryzae* Hydrophobin RolA on Hydrophobic and Charged Solid Surfaces. Druzhinina IS, ed. *Appl Environ Microbiol.* 2022;88(6). doi:10.1128/aem.02087–21
28. Miyamoto A, Yamanaka T, Suzuki S, et al. Oligomeric state of the aspartate:alanine transporter from *Tetragenococcus halophilus*. *J Biochem.* 2022;172(4):217–224. doi:10.1093/jb/mvac057
29. Yu Z, Matsukawa N, Saigusa D, et al. Plasma metabolic disturbances during pregnancy and postpartum in women with depression. *iScience.* 2022;25(12):105666. doi:10.1016/j.isci.2022.105666
30. Saeidi S, Kim S, Guillen-Quispe YN, et al. Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 directly binds and stabilizes Nrf2 in breast cancer. *FASEB J.* 2022;36(1). doi:10.1096/fj.202100776RR
31. Kitamura H, Oishi T, Murakami S, et al. Establishment of Neh2-Cre:tdTomato reporter mouse for monitoring the exposure history to electrophilic stress. *Free Radic Biol Med.* 2022;193:610–619. doi:10.1016/j.freeradbiomed.2022.11.004
32. Kitamura H, Takeda H, Motohashi H. Genetic, metabolic and immunological features of cancers with *NRF2* addiction. *FEBS Lett.* 2022;596(16):1981–1993. doi:10.1002/1873-3468.14458
33. Nakai T, Saigusa D, Iwamura Y, et al. Esterification promotes the intracellular accumulation of roxadustat, an activator of hypoxia-inducible factors, to extend its effective duration. *Biochem Pharmacol.* 2022;197:114939. doi:10.1016/j.bcp.2022.114939
34. Kushima I, Aleksic B, Kimura H, et al. X chromosome aneuploidies and schizophrenia: association analysis and phenotypic characterization. *Psychiatry Clin Neurosci.* 2022;76(12):667–673. doi:10.1111/pcn.13474

35. Panda H, Suzuki M, Naito M, et al. Halofuginone micelle nanoparticles eradicate Nrf2-activated lung adenocarcinoma without systemic toxicity. *Free Radic Biol Med.* 2022;187:92–104. doi:10.1016/j.freeradbiomed.2022.05.017
36. Baird L, Kensler TW, Yamamoto M. Novel NRF2-activated cancer treatments utilizing synthetic lethality. *IUBMB Life.* 2022;74(12):1209–1231. doi:10.1002/iub.2680
37. Suzuki S, Chiba F, Kimura T, Kon N, Nanatani K, Abe K. Conformational transition induced in the aspartate:alanine antiporter by L-Ala binding. *Sci Rep.* 2022;12(1):15871. doi:10.1038/s41598-022-19974-z
38. Jacobsen JOB, Baudis M, Baynam GS, et al. The GA4GH Phenopacket schema defines a computable representation of clinical data. *Nat Biotechnol.* 2022;40(6):817–820. doi:10.1038/s41587-022-01357-4
39. Hishinuma E, Narita Y, Obuchi K, et al. Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population. *Front Pharmacol.* 2022;13. doi:10.3389/fphar.2022.930470
40. Otsuki A, Okamura Y, Ishida N, et al. Construction of a trio-based structural variation panel utilizing activated T lymphocytes and long-read sequencing technology. *Commun Biol.* 2022;5(1):991. doi:10.1038/s42003-022-03953-1
41. Kobayashi T, Kobayashi M, Minegishi N, et al. Design and Progress of Child Health Assessments at Community Support Centers in the Birth and Three-Generation Cohort Study of the Tohoku Medical Megabank Project. *Tohoku J Exp Med.* Published online 2022:2022.J103. doi:10.1620/tjem.2022.J103
42. Liu Y, Uruno A, Saito R, et al. Nrf2 deficiency deteriorates diabetic kidney disease in Akita model mice. *Redox Biol.* 2022;58:102525. doi:10.1016/j.redox.2022.102525
43. Kato K, Nakayoshi T, Nagura A, et al. Structural investigation of pathogenic variants in dihydropyrimidinase using molecular dynamics simulations. *J Mol Graph Model.* 2022;117:108288. doi:10.1016/j.jmgm.2022.108288
44. Shimizu M, Hirose N, Kato M, et al. Further survey of genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found in an updated database of genome resources and identified by phenotyping for trimethylaminuria. *Drug Metab Pharmacokinet.* 2022;46:100465. doi:10.1016/j.dmpk.2022.100465
45. Ohneda K, Hamanaka Y, Kawame H, et al. Returning individual genomic results to population-based cohort study participants with BRCA1/2 pathogenic variants. *Breast Cancer.* Published online September 26, 2022. doi:10.1007/s12282-022-01404-7

46. Mahajan A, Spracklen CN, Zhang W, et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. *Nat Genet.* 2022;54(5):560–572. doi:10.1038/s41588-022-01058-3
47. Wakamori S, Taguchi K, Nakayama Y, et al. Nrf2 protects against radiation-induced oral mucositis via antioxidation and keratin layer thickening. *Free Radic Biol Med.* 2022;188:206–220. doi:10.1016/j.freeradbiomed.2022.06.239
48. Iemura K, Anzawa H, Funayama R, et al. High levels of chromosomal instability facilitate the tumor growth and sphere formation. *Cancer Sci.* 2022;113(8):2727–2737. doi:10.1111/cas.15457
49. Ganaha A, Hishinuma E, Kaname T, Hiratsuka M, Kondo S, Tono T. Rapid Genetic Diagnosis for Okinawan Patients with Enlarged Vestibular Aqueduct Using Single-Stranded Tag Hybridization Chromatographic Printed-Array Strip. *J Clin Med.* 2022;11(4):1099. doi:10.3390/jcm11041099
50. Katsuoka F, Otsuki A, Hatanaka N, Okuyama H, Yamamoto M. Target Gene Diversity of the Nrf1-MafG Transcription Factor Revealed by a Tethered Heterodimer. *Mol Cell Biol.* 2022;42(3). doi:10.1128/mcb.00520-21
51. Siamoglou S, Koromina M, Hishinuma E, et al. Identification and functional validation of novel pharmacogenomic variants using a next-generation sequencing-based approach for clinical pharmacogenomics. *Pharmacol Res.* 2022;176:106087. doi:10.1016/j.phrs.2022.106087
52. A Pilot Study for Return of Individual Pharmacogenomic Results to Population-Based Cohort Study Participants. *JMA J.* 2022;5(2). doi:10.31662/jmaj.2021-0156
53. Nishiumi S, Izumi Y, Hirayama A, et al. Comparative Evaluation of Plasma Metabolomic Data from Multiple Laboratories. *Metabolites.* 2022;12(2):135. doi:10.3390/metabo12020135
54. Edamitsu T, Taguchi K, Okuyama R, Yamamoto M. AHR and NRF2 in Skin Homeostasis and Atopic Dermatitis. *Antioxidants.* 2022;11(2):227. doi:10.3390/antiox11020227
55. Sugawara J, Ishikuro M, Obara T, et al. Maternal Baseline Characteristics and Perinatal Outcomes: The Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study. *J Epidemiol.* 2022;32(2):JE20200338. doi:10.2188/jea.JE20200338